Derek Archila
Stock Analyst at Wells Fargo
(3.76)
# 736
Out of 4,970 analysts
183
Total ratings
50%
Success rate
8.46%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintains: Overweight | $44 → $38 | $22.76 | +66.96% | 4 | Aug 20, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Overweight | $123 | $69.68 | +76.52% | 1 | Aug 20, 2025 | |
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $1.03 | +192.68% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $1.54 | +29.87% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $198.08 | +48.93% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.78 | +181.69% | 5 | Aug 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $27 → $26 | $18.70 | +39.04% | 2 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $19 → $16 | $7.62 | +109.97% | 7 | Aug 7, 2025 | |
| INCY Incyte | Upgrades: Overweight | $67 → $89 | $85.44 | +4.17% | 9 | Aug 6, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $741 → $756 | $733.20 | +3.11% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.60 | +269.97% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $104.45 | +23.50% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $42.23 | +25.50% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $25 | $5.47 | +357.04% | 2 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $26 → $29 | $28.65 | +1.22% | 12 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $14.12 | +27.48% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $9.12 | +174.27% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $4.91 | +103.87% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.64 | +814.63% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $37.38 | -3.69% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $21.08 | +141.94% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $14.10 | -0.71% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $3.80 | +136.84% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $16.12 | +179.24% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $2.67 | +349.44% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $3.61 | +564.82% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.61 | +322.26% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.16 | +364.04% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.54 | +688.95% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.58 | +222.58% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.88 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.90 | +505.02% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $74.38 | -44.88% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.98 | +968.09% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $9.34 | +542.40% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.66 | +522.32% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.30 | +3,746.15% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $18.80 | +171.28% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $23.26 | +278.33% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $26.75 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $18.49 | - | 2 | Aug 3, 2017 |
Celldex Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $22.76
Upside: +66.96%
Soleno Therapeutics
Aug 20, 2025
Initiates: Overweight
Price Target: $123
Current: $69.68
Upside: +76.52%
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.03
Upside: +192.68%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.54
Upside: +29.87%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $198.08
Upside: +48.93%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.78
Upside: +181.69%
Viridian Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $18.70
Upside: +39.04%
Arvinas
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $7.62
Upside: +109.97%
Incyte
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $85.44
Upside: +4.17%
argenx SE
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $733.20
Upside: +3.11%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.60
Upside: +269.97%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $104.45
Upside: +23.50%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $42.23
Upside: +25.50%
Jun 20, 2025
Maintains: Overweight
Price Target: $17 → $25
Current: $5.47
Upside: +357.04%
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $28.65
Upside: +1.22%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $14.12
Upside: +27.48%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $9.12
Upside: +174.27%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.91
Upside: +103.87%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.64
Upside: +814.63%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $37.38
Upside: -3.69%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $21.08
Upside: +141.94%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $14.10
Upside: -0.71%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $3.80
Upside: +136.84%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $16.12
Upside: +179.24%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $2.67
Upside: +349.44%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $3.61
Upside: +564.82%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.61
Upside: +322.26%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.16
Upside: +364.04%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.54
Upside: +688.95%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $5.58
Upside: +222.58%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.88
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.90
Upside: +505.02%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $74.38
Upside: -44.88%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.98
Upside: +968.09%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $9.34
Upside: +542.40%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.66
Upside: +522.32%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.30
Upside: +3,746.15%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $18.80
Upside: +171.28%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $23.26
Upside: +278.33%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $26.75
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $18.49
Upside: -